Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for prevention of bleomycin-related pulmonary fibrosis in malignant ovarian germ cell tumor patients
ChiCTR2300070492Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) comparing Nintedanib group with Placebo group (2 arms). Primary endpoints: Absolute decline in forced vital capacity, Percent decline in predicted forced vital capacity and 1 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on ChiCTR2300070492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070492.